Novo Nordisk : 2021 clinical newsflow focused on GLP-1 and H2
>The market welcomes the good performance from Rybelsus in our view - Novo Nordisk's share price reacted well yesterday to the publication of the Q4 (+2.7%), yet as we indicated, the implicit guidance of operating profit for 2021 (between DKK 53.0bn and DKK 55.2bn DKK) is between 1% and 3% below market expectations (DKK 55.9bn according to the consensus collected by the company). We think that it is the very good commercial performance of the growth drivers that has b...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.